Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of August 2018, with a report date of August 16, 2018. The filing announces the receipt of a second tranche of funding under a finance contract with the European Investment Bank (EIB) to support the development and marketing of the product candidate M-001.
Key Financial Metrics
- Debt Financing: The Company received a second tranche of €6 million from the EIB on August 14, 2018.
- Total Loan Received: Cumulative funding received from the EIB is now €12 million.
- Loan Capacity: The original finance contract allows for up to €20 million, covering up to 50% of expected development and marketing costs for M-001.
- Revenue, Profit, Cash Flow, Margins, Liquidity: The filing text does not provide a clear value for these specific metrics.
Material Changes
The primary material change is the disbursement of the second €6 million tranche, increasing the total debt obligation from the EIB to €12 million. This follows a previous tranche of €6 million received in June 2018.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of the funding receipt. The filing references a press release (Exhibit 99.1) for further details. No specific financial guidance, risk factors, or contingencies are detailed within the text of this specific Form 6-K.
Investor Verification Checklist
- Verify the terms of the EIB finance contract, including interest rates, repayment schedules, and covenants.
- Confirm the status of the M-001 product candidate development and marketing milestones required to trigger future tranches.
- Review the attached press release (Exhibit 99.1) for additional details on the use of proceeds.
- Check subsequent filings for the disbursement of the remaining potential €8 million under the €20 million facility.